These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23160401)

  • 1. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes.
    Simsek S; de Galan BE
    Curr Opin Lipidol; 2012 Dec; 23(6):540-7. PubMed ID: 23160401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
    Chrysant SG; Chrysant GS
    Am J Cardiol; 2012 Jun; 109(11):1681-5. PubMed ID: 22425330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential cardiovascular effects of incretin-based therapies.
    Deacon CF; Marx N
    Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 9. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
    Cariou B
    Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in incretin-based therapies: the current state of the field.
    Robertson C
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():631-41. PubMed ID: 19900194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.
    Farr S; Adeli K
    Curr Opin Lipidol; 2012 Feb; 23(1):56-61. PubMed ID: 22123671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors.
    Tanaka T; Nangaku M; Nishiyama A
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):476-81. PubMed ID: 21738030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
    Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism].
    Winkler G
    Orv Hetil; 2013 Feb; 154(7):248-55. PubMed ID: 23395788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin therapy for type 2 diabetes mellitus.
    Klonoff DC
    Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.
    Martin JH; Deacon CF; Gorrell MD; Prins JB
    Intern Med J; 2011 Apr; 41(4):299-307. PubMed ID: 21299778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.